224 related articles for article (PubMed ID: 25755562)
21. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins.
Roche B; Roque-Afonso AM; Sebagh M; Delvart V; Duclos-Vallee JC; Castaing D; Samuel D
Liver Transpl; 2010 Jul; 16(7):885-94. PubMed ID: 20583085
[TBL] [Abstract][Full Text] [Related]
22. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
Karlas T; Hartmann J; Weimann A; Maier M; Bartels M; Jonas S; Mössner J; Berg T; Tillmann HL; Wiegand J
Transpl Infect Dis; 2011 Jun; 13(3):299-302. PubMed ID: 21159112
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis B recurrence after liver transplantation: a single center experiences and review the literature.
Dehghani SM; Taghavi SA; Geramizadeh B; Nikeghbalian S; Derakhshan N; Malekpour A; Malek-Hosseini SA
Hepat Mon; 2013 Jan; 13(1):e6609. PubMed ID: 23483668
[TBL] [Abstract][Full Text] [Related]
24. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
Cholongitas E; Goulis I; Antoniadis N; Fouzas I; Imvrios G; Giakoustidis D; Giouleme O; Papanikolaou V; Akriviadis E; Vasiliadis T
Transpl Infect Dis; 2016 Oct; 18(5):667-673. PubMed ID: 27421122
[TBL] [Abstract][Full Text] [Related]
25. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients.
Fernández I; Loinaz C; Hernández O; Abradelo M; Manrique A; Calvo J; Manzano M; García A; Cambra F; Castellano G; Jiménez C
Transpl Infect Dis; 2015 Oct; 17(5):695-701. PubMed ID: 26257166
[TBL] [Abstract][Full Text] [Related]
26. Prevention and risk factors of hepatitis B recurrence after living donor liver transplantation.
Na GH; Kim DG; Han JH; Kim EY; Lee SH; Hong TH; You YK; Choi JY
J Gastroenterol Hepatol; 2014 Jan; 29(1):151-6. PubMed ID: 24117684
[TBL] [Abstract][Full Text] [Related]
27. HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration.
Rosenau J; Kreutz T; Kujawa M; Bahr MJ; Rifai K; Hooman N; Finger A; Michel G; Nashan B; Kuse ER; Klempnauer J; Tillmann HL; Manns MP
J Hepatol; 2007 Apr; 46(4):635-44. PubMed ID: 17316869
[TBL] [Abstract][Full Text] [Related]
28. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients.
Stärkel P; Stoffel M; Lerut J; Horsmans Y
Liver Transpl; 2005 Oct; 11(10):1228-34. PubMed ID: 16184571
[TBL] [Abstract][Full Text] [Related]
29. Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis.
Wadhawan M; Gupta S; Goyal N; Taneja S; Kumar A
Liver Transpl; 2013 Sep; 19(9):1030-5. PubMed ID: 23788470
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis B prophylaxis in living donor liver transplantation: single center experience.
Yaprak O; Dayangac M; Balci D; Bas K; Yuzer Y; Tokat Y
Hepatogastroenterology; 2010; 57(102-103):1178-82. PubMed ID: 21410054
[TBL] [Abstract][Full Text] [Related]
31. Successful clinical and virological outcomes of liver transplantation for HDV/HBV-related disease after long-term discontinuation of hepatitis B immunoglobulins.
Lenci I; Tariciotti L; Angelico R; Milana M; Signorello A; Manzia TM; Toti L; Tisone G; Angelico M; Baiocchi L
Clin Transplant; 2023 Jun; 37(6):e14971. PubMed ID: 36928864
[TBL] [Abstract][Full Text] [Related]
32. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
[TBL] [Abstract][Full Text] [Related]
33. The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence.
Idilman R; Akyildiz M; Keskin O; Gungor G; Yilmaz TU; Kalkan C; Dayangac M; Cinar K; Balci D; Hazinedaroglu S; Tokat Y
Clin Transplant; 2016 Oct; 30(10):1216-1221. PubMed ID: 27409074
[TBL] [Abstract][Full Text] [Related]
34. Antiviral Combination Therapy With Low-Dose Hepatitis B Immunoglobulin for the Prevention of Hepatitis B Virus Recurrence in Liver Transplant Recipients: A Single-Center Experience.
Akcam AT; Ulku A; Rencuzogullari A; Eray IC; Okoh A; Kuran S; Dalcı K; Yalav O; Parsak CK; Sakman G; Demiryurek H
Transplant Proc; 2015 Jun; 47(5):1445-9. PubMed ID: 26093739
[TBL] [Abstract][Full Text] [Related]
35. Long-term efficacy of hepatitis B vaccination as post-transplant prophylaxis in hepatitis B surface antigen (HBsAg) positive recipients and HBsAg negative recipients of anti-hepatitis B core positive grafts.
Yoshizawa A; Yamashiki N; Ueda Y; Kaido T; Okajima H; Marusawa H; Chiba T; Uemoto S
Hepatol Res; 2016 May; 46(6):541-51. PubMed ID: 26348993
[TBL] [Abstract][Full Text] [Related]
36. A new scheme with infusion of hepatitis B immunoglobulin combined with entecavir for prophylaxis of hepatitis B virus recurrence among liver transplant recipients.
Chen G; Liu H; Hu ZQ; Bai JH; Liu QY; Zhao YP; Gan XM; Wang F; Wang DD; Ma LJ; Li L
Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):901-6. PubMed ID: 26011237
[TBL] [Abstract][Full Text] [Related]
37. Role of nucleoside/nucleotide analogues and low-dose hepatitis B immune globülin in prophylaxis of hepatitis B recurrence among cadaveric liver transplant recipients.
Ajayi T; Luu H; Saberi B; Hamilton JP; Konduk BT; Özşeker B; Al Khalloufi K; Pustavoitau A; Philosophe B; Cameron AM; Gürakar A
Turk J Gastroenterol; 2018 Jan; 29(1):61-66. PubMed ID: 29391309
[TBL] [Abstract][Full Text] [Related]
38. Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation.
Di Paolo D; Tisone G; Piccolo P; Lenci I; Zazza S; Angelico M
Transplantation; 2004 Apr; 77(8):1203-8. PubMed ID: 15114086
[TBL] [Abstract][Full Text] [Related]
39. Entecavir and other nucleos(t)ide analogs prophylaxis in hepatitis B virus-related liver transplantation: long-term efficacy and safety.
Darweesh SK; Gad AA; Akroof K; ElLatif ZA
Eur J Gastroenterol Hepatol; 2019 May; 31(5):607-612. PubMed ID: 30724767
[TBL] [Abstract][Full Text] [Related]
40. Role of lower dose hepatitis B immune globulin prophylaxis in liver transplantation: A single center perspective.
Edwards D; Lin J; Toman L; Gurakar M; Pustavoitau A; Kohli R; Wesson R; Ottmann SE; Dao D; Gurakar A; Kim A
Hepatol Forum; 2023 Jan; 4(1):3-6. PubMed ID: 36843892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
